SuperworthLifevantage EPS LFVN
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.40
- Latest quarter, Q4 FY26
- $0.10
- −33% on a year earlier
- Fiscal year 2026
- $0.40
- −46% on the year before
Lifevantage's earnings per share was $0.40 over the twelve months to Jun 30, 2026, down 46% on a year earlier.
In its latest quarter, Q4 FY26, it was $0.10, down 33% on the same quarter a year before.
Over the five fiscal years to FY2026 it shrank 15% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | $0.40 | −46% |
| FY2025 | $0.74 | +222% |
| FY2024 | $0.23 | +10% |
| FY2023 | $0.21 | −13% |
| FY2022 | $0.24 | −73% |
| FY2021 | $0.90 | +14% |
| FY2020 | $0.79 | +58% |
| FY2019 | $0.50 | +22% |
| FY2018 | $0.41 | +273% |
| FY2017 | $0.11 | −73% |
| FY2016 | $0.41 | −11% |
| FY2015 | $0.46 | −34% |
| FY2014 | $0.70 | +67% |
| FY2013 | $0.42 | +0% |
| FY2012 | $0.42 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | $0.10 | −33% | $0.40 | |
| Q3 FY26 | $0.11 | −58% | $0.45 | |
| Q2 FY26 | $0.02 | −89% | $0.60 | |
| Q1 FY26 | $0.17 | +21% | $0.77 | |
| Q4 FY25 | $0.15 | +50% | $0.74 | |
| Q3 FY25 | $0.26 | +100% | $0.69 | |
| Q2 FY25 | $0.19 | n/a | $0.56 | |
| Q1 FY25 | $0.14 | +180% | $0.32 | |
| Q4 FY24 | $0.10 | −38% | $0.23 | |
| Q3 FY24 | $0.13 | +63% | $0.29 | |
| Q2 FY24 | −$0.05 | n/a | $0.24 | |
| Q1 FY24 | $0.05 | +0% | $0.21 |
Against its peers
Companies in Drug Manufacturers - General nearest Lifevantage's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| Peer median | $0.65 |
Where Lifevantage ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Lifevantage
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.